Scarica l'app Stockscreener
86.80
0.88%
-0.81
Precedente Chiudi:
$87.61
Aprire:
$85.66
Volume 24 ore:
850.58K
Relative Volume:
0.82
Capitalizzazione di mercato:
$5.36B
Reddito:
$360.35M
Utile/perdita netta:
$-149.57M
Rapporto P/E:
-29.32
EPS:
-2.96
Flusso di cassa netto:
$-81.27M
1 W Prestazione:
-7.43%
1M Prestazione:
+3.81%
6M Prestazione:
-32.08%
1 anno Prestazione:
-18.47%
Intervallo 1D:
$84.74
$87.67
Intervallo di 1 settimana:
$77.10
$94.72
Portata 52W:
$77.10
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Nome
Glaukos Corporation
Settore
Industria
Telefono
949-367-9600
Indirizzo
1 GLAUKOS WAY, ALISO VIEJO, CA
Confronta GKOS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
86.73 | 5.36B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
132.86 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.28 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.31 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.45 | 108.80B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.33 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-12-06 | Iniziato | UBS | Buy |
| 2024-12-02 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Iniziato | Truist | Buy |
| 2023-11-08 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Iniziato | Mizuho | Neutral |
| 2022-12-19 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-14 | Ripresa | Stephens | Overweight |
| 2022-10-04 | Iniziato | Needham | Buy |
| 2022-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2022-02-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2021-11-03 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Aggiornamento | Citigroup | Sell → Neutral |
| 2020-12-09 | Iniziato | Oppenheimer | Perform |
| 2020-11-17 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Iniziato | Jefferies | Hold |
| 2020-03-05 | Iniziato | Citigroup | Sell |
| 2020-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Aggiornamento | Berenberg | Hold → Buy |
| 2019-12-12 | Downgrade | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Iniziato | BTIG Research | Neutral |
| 2018-08-30 | Iniziato | Berenberg | Hold |
| 2018-08-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Reiterato | Stifel | Hold |
| 2018-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Downgrade | Stifel | Buy → Hold |
| 2018-03-01 | Reiterato | Cantor Fitzgerald | Buy |
| 2017-03-02 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Aggiornamento | Stifel | Hold → Buy |
| 2016-10-27 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Glaukos Corporation Borsa (GKOS) Ultime notizie
Glaukos projects 2025 sales in the $475M-$485M range with strong iDose ramp - MSN
Decoding Glaukos Corp (GKOS): A Strategic SWOT Insight - GuruFocus
Stephens cuts Glaukos stock price target to $115 from $140 By Investing.com - Investing.com South Africa
What 11 Analyst Ratings Have To Say About Glaukos - Benzinga
Stephens cuts Glaukos stock price target to $115 from $140 - Investing.com Australia
GKOS: Stephens & Co. Lowers Price Target for Glaukos to $115 | GKOS Stock News - GuruFocus
Glaukos Corporation (NYSE:GKOS) Q1 2025 Earnings Call Transcript - MSN
Glaukos (GKOS) Price Target Reduced by Stephens Following Earnin - GuruFocus
Glaukos (GKOS) Price Target Reduced by Stephens Following Earnings Report | GKOS Stock News - GuruFocus
Glaukos First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
How To Trade (GKOS) - news.stocktradersdaily.com
Glaukos Corp. Reports Record Revenue and Growth - TipRanks
Glaukos (GKOS) Sees Price Target Reduction by Stifel Analyst | G - GuruFocus
Needham cuts Glaukos stock price target to $115, maintains Buy By Investing.com - Investing.com South Africa
JPMorgan cuts Glaukos stock target to $100 from $160 By Investing.com - Investing.com Nigeria
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
Glaukos (GKOS) Price Target Revised Down to $135 by Truist Securities | GKOS Stock News - GuruFocus
Needham Maintains Buy Rating for Glaukos (GKOS) with Adjusted Pr - GuruFocus
GKOS Stock Downgraded by Wells Fargo | GKOS Stock News - GuruFocus
Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Wells downgrades Glaukos with iDose growth priced in - TipRanks
GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline - Yahoo Finance
Truist Adjusts Price Target on Glaukos Corp to $135 From $140, Maintains Buy Rating - marketscreener.com
Glaukos stock hits 52-week low at $77.69 amid market challenges - Investing.com India
Glaukos (GKOS) Target Price Cut by Needham Amidst Revenue Beats - GuruFocus
Glaukos (GKOS) Target Price Cut by Needham Amidst Revenue Beats | GKOS Stock News - GuruFocus
Glaukos (GKOS) Receives Adjusted Price Target but Maintains Buy Rating | GKOS Stock News - GuruFocus
Needham cuts Glaukos stock price target to $115, maintains Buy - Investing.com
Glaukos (GKOS) Downgraded by Wells Fargo with Reduced Price Targ - GuruFocus
S&P 500 Futures Rise in Premarket Trading; McCormick Vtg, Glaukos Lag - Barron's
JPMorgan cuts Glaukos stock target to $100 from $160 - Investing.com
GLAUKOS Corp SEC 10-Q Report - TradingView
Glaukos Corp (GKOS) Q1 2025 Earnings Call Highlights: Record Sales and Strategic Growth Amid ... - Yahoo Finance
Glaukos Corp (GKOS) Q1 2025 Earnings Call Highlights: Record Sal - GuruFocus
Glaukos Corp. Reports Strong Q1 2025 Growth - TipRanks
Earnings call transcript: Glaukos Corp beats Q1 2025 EPS forecast, stock falls - Investing.com Nigeria
Glaukos: Q1 Earnings Snapshot - MySA
Glaukos Corp earnings beat by $0.13, revenue topped estimates - Investing.com Canada
Why Glaukos Shares Are Sliding Despite Strong Q1 - TipRanks
Glaukos shares fall as Q1 earnings beat overshadowed by outlook - Investing.com Nigeria
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Glaukos Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Glaukos (GKOS) Reports Surpassing Revenue Expectations in Q1 | G - GuruFocus
Glaukos Corp Q1 2025 Earnings: EPS Loss of $0.32 Beats Estimate, Revenue Surpasses Expectations at $106.7 Million - GuruFocus
Glaukos Reports Record Q1 2025 Net Sales Growth - TipRanks
Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q1 Loss $-0.22 Per Share, vs. FactSet Est of $-0.35 - marketscreener.com
Glaukos Announces First Quarter 2025 Financial Results - Business Wire
Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting - BioSpace
Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Glaukos Corporation Azioni (GKOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
12.05%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):